SLC12A3 and coronary artery disorder: Genetically proxied NCC inhibition was associated with lower risk of coronary artery disease (per 1 mm Hg lower SBP: OR 0.81, 95% CI 0.81, 95% CI 0.71 to 0.93, P = 3.2 × 10−3) and was weakly associated with lower risk of stroke (OR 0.89, 95% CI 0.78 to 1.02; P = 0.10).